With the rollout of its new over-the-counter continuous glucose monitor, Abbott aims to help its customers speak the hidden language of their bodies’ response to food, exercise and stress.

On the heels of an FDA rejection for its chief rival Novo Nordisk, Eli Lilly is gaining ground in the race to bring a once-weekly insulin to the U.S.

The bacterium Chlamydia trachomatis is best known for infecting genitals, causing the sexually transmitted infection (STI) known as chlamydia. But a new study has found that these sneaky cells can also infiltrate our guts, building a hidden supply of bacteria that could then leak to the genitals and cause reoccurring infections.

Parexel, a global contract research organization headquartered in Durham, North Carolina, is beefing up its ability to gather real-world data by bringing Mike D’Ambrosio on board as senior vice president and global head of real world research.

Abbott has launched a pivotal clinical trial to see if its deep-brain stimulation approach can make headway against treatment-resistant depression.

A new type of mpox, clade Ib, has been spreading rapidly within the Democratic Republic of Congo and leaking outside the African nation’s borders since Sept. 2023. In response, the World Health Organization (WHO) declared the outbreak a public health emergency of international concern (PHEIC) last month, the second such declaration for an mpox variant in the past two years.

Athira Pharma’s tumultuous journey to phase 2/3 Alzheimer’s disease data has ended in failure. The trial found fosgonimeton was no better than placebo on the primary and key secondary endpoints, driving investors to cut the cord holding up the biotech’s stock price.

Embecta has secured an FDA clearance for its first wearable insulin delivery system, with a patch pump designed for people with either Type 1 or Type 2 diabetes.

Vaxcyte unveiled what analysts called “stunning” phase 1/2 data for its 31-valent pneumococcal vaccine candidate that, if replicated in a large pivotal study, could pose a serious threat to Pfizer’s stalwart Prevnar 20.

Though Illumina said goodbye to Grail this past summer—after butting heads for years with antitrust regulators and activist investors, while enduring heavy fines and orders to split—the European Union’s highest court now says the company may have had a point from the beginning.